Table 5.
TG and Non-HDLC in 7 subjects, where the Lovaza sequence was 4, 8, 12, 4, 4, 4, 4 g/day
| Visit | Dosage (g/day) |
TG (mg/dl) |
Non-HDLC (mg/dl) |
||||||
|---|---|---|---|---|---|---|---|---|---|
| Mean ± SD | median | % change, p vs Visit 0 | p* (vs former Visit) | Mean ± SD | median | % change, p vs Visit 0 | p* (vs former Visit) | ||
| 0 |
0 |
1075 ±525 |
857 |
|
|
245 ±88 |
214 |
|
|
| 1 |
4 |
672 ±247 |
587 |
−37%, .006 |
|
217 ±62 |
223 |
−11%, |
|
| 2 |
8 |
577 ±189 |
666 |
−46%, .0009 |
NS |
203 ±44 |
199 |
−17%, .01 |
NS |
| 3 |
12 |
428 ±184 |
443 |
−60%, <.0001 |
.03 |
192 ±61 |
164 |
−22%, .003 |
NS |
| 4 |
4 |
561 ±244 |
554 |
.0006 |
.03 |
203 ±49 |
185 |
.01 |
NS |
| 5 |
4 |
538 ±115 |
593 |
.0004 |
|
205 ±44 |
233 |
.01 |
|
| 6 |
4 |
459 ±171 |
502 |
<.0001 |
|
189 ±31 |
185 |
.001 |
|
| 7 |
4 |
430 ±191 |
395 |
<.0001 |
|
171 ±43 |
164 |
.0002 |
|
| TG decreasing slope during the first 3 months, when the Lovaza dose was increased from 0 to 12 g/day, p=.0018 | Non-HDLC decreasing slope during the first 3 months, when the Lovaza dose was increased from 0 to 12 g/day, p=.016 | ||||||||
p: comparison of Least-square means using Mixed model.
p*: paired Wilcoxon test for the change from Visit 1 to Visit 2 (dosage from 4 g/day to 8); from Visit 2 to Visit 3 (dosage from 8 g/day to 12); from Visit 3 to Visit 4 (dosage from 12 g/day to 4).